NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Yamo Pharmaceuticals

Yamo Pharmaceuticals

Private
New York City, New YorkHealthcare & Life Scienceshttps://yamopharma.com/

Last Round

VC Round

Nov 10, 2021

Company Overview

Yamo Pharmaceuticals is a clinical-stage biotechnology company developing L1-79, an oral therapy designed to treat the core social-interaction symptoms of Autism Spectrum Disorder.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

autism spectrum disorderASDdrug developmentclinical-stage pharmabiotech startupclinical trialstyrosine hydroxylase inhibitorneuropsychiatric drugCNS therapydrug discoveryFDA fast tracksmall molecule drugbiopharmaorphan drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Yamo Pharmaceuticals Comparables

Compare Yamo Pharmaceuticals with similar companies based on industry and business-model similarity.

Yamo Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Curemark
85%
Astrogen, Inc.
83%
PaxMedica, Inc.
82%

Yamo Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundNov 10, 2021

Key People

Founding team and executive leadership

Brian Cahill

Chief Financial Officer

Executive Team

Eugene Prahin

Founding Team Member Chief Financial Officer Inception to Nov-24 Chief Administrative Officer

Founding Team

Yamo Pharmaceuticals Investors

Notable investors and investment history

Yamo Pharmaceuticals investors
InvestorRounds
Autism Impact FundVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 19, 2026

    Monthly visitors increased 46% MoM.

  • Nov 10, 2021

    Autism Impact Fund led the round.

Yamo Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Yamo Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Yamo Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range10
Year Founded2015
Last FundingNov 10, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.